Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed 53 enrolled M.D. Anderson Cancer Center Bristol-Myers Squibb · collab OSI Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of the Phase I portion of this study is to find the highest tolerable dose of the combination of dasatinib and erlotinib hydrochloride that can be given to patients with advanced solid tumors. The goal of the Phase II portion of this study is to learn if this combination is effective when given to patients with non-small cell lung cancer. The safety of this combination will be studied in both phases.

Timeline

Start: 2009-02
Primary completion: 2014-06
Completion: 2014-06

Publications

Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist. 2014 Oct;19(10):1040-1. doi: 10.1634/theoncologist.2014-0228. Epub 2014 Aug 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	150 mg	Oral
Subject	dasatinib anhydrous	Small molecule	70 mg	Oral

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Summary

Timeline

Publications

Drugs

Indications